SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Starlight who wrote (898)5/25/2001 5:28:45 PM
From: OldAIMGuy  Read Replies (1) | Respond to of 1154
 
Hi Betty, As usual, I let some shares go with the rise. This time it was 5% of my position at $15.85. That turned a nice LIFO profit for me of about 36% since November.

All in all GENE's done pretty well by me. I was ready to sit back for a year and let my holdings rest, but this recent surge is causing my program to beg me to lighten up!

Best regards, Tom



To: Starlight who wrote (898)5/29/2001 11:13:09 AM
From: Thomas M.  Respond to of 1154
 
<< Genome Therapeutics' other big pharma alliances include work with AstraZeneca on a prophylactic and therapeutic vaccination against ulcer-causing bacterium Helicobacter pylori. "We would expect them to move this into the clinic later this year or early in the spring of next year," said Richard Gill, President and COO. >>

I don't recall this happening yet. It would be a nice piece of news.

Tom


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News